FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, Cristiana Lupi, Elisa Sensi, Sara Lonardi, Silvia Mezi, Gianluca Tomasello, Monica Ronzoni, Alberto Zaniboni, Giuseppe Tonini, Chiara Carlomagno, Giacomo Allegrini, Silvana Chiara, Mauro D’Amico, Cristina Granetto, Marina Elena Cazzaniga, Luca Boni, Gabriella Fontanini, Alfredo Falcone
The Lancet Oncology, 2015
Abstract
An abstract is not available for this record. Please visit the publisher website for more details.